EPICART
DNA methylation kit for the prediction of the response to CAR T-cell therapy.
EPICART is a risk stratification tool that employs a methylation signature that accurately predicts the treatment outcome of B-malignancy patients treated with CD19 CAR T-cell therapy.
Més informació